As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

Just one day af­ter block­buster Lyn­parza got ac­cess to an­oth­er in­di­ca­tion in Chi­na, its Big Phar­ma own­ers have de­cid­ed to with­draw it in cer­tain pa­tients af­ter re­view­ing Phase III da­ta.

The two com­pa­nies that work to­geth­er on Lyn­parza de­cid­ed to re­call one of the in­di­ca­tions sev­er­al weeks ago in a spe­cif­ic type of ovar­i­an can­cer, Lyn­parza’s first in­di­ca­tion when it was first FDA-ap­proved in 2014. Ini­tial da­ta showed that rates of over­all sur­vival in pa­tients with at least three rounds of chemo be­fore get­ting on the PARP in­hibitor were low­er than in pa­tients with less pre­vi­ous chemo treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER